RBC Capital Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $6
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Gregory Renza has initiated coverage on Cormedix (NASDAQ:CRMD) with an Outperform rating and a price target of $6.
August 10, 2023 | 12:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has initiated coverage on Cormedix with an Outperform rating and a price target of $6, which could positively impact the stock's performance.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, RBC Capital's Outperform rating and $6 price target for Cormedix suggest a positive outlook for the stock, which could lead to an increase in its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100